Roche Group posts strong sales growth in the first quarter
11 April 2013 | By Roche
Group sales increase 6% at CER1 to 11.6 billion Swiss francs...
List view / Grid view
11 April 2013 | By Roche
Group sales increase 6% at CER1 to 11.6 billion Swiss francs...
4 April 2013 | By Roche
The Elecsys Calcitonin marker expands Roche’s portfolio for improved thyroid management
18 March 2013 | By Roche
The EMA has expanded the approval of Pegasys...
6 March 2013 | By Roche
Viral load test uses a novel dual-probe approach designed to manage patients being treated with antiviral therapies...
5 March 2013 | By Roche
Roche to inform about plans for succession in autumn 2013...
5 March 2013 | By Roche
Roche announced that the EMA has approved PERJETA (pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC)...
26 February 2013 | By Roche
Independent body to grant access to patient-level data for scientific review...
22 February 2013 | By Roche
New personalised medicine helped people in Phase III study live longer, compared to standard treatment...
31 January 2013 | By Roche
Positive results from stage 1 of CLL11...
In November 2012, the US Food and Drug Administration accepted the use of the MycoTOOL® PCR Mycoplasma Detection Kit as a release method for a biopharmaceutical product manufactured by Roche Applied Science intended for distribution in the United States.
24 January 2013 | By Roche
Roche announced that the US FDA approved a new use of Avastin...
15 January 2013 | By Roche
John C. Reed, M.D., Ph.D., has been appointed Head of Roche pRED and member of the enlarged Corporate Executive Committee...
22 December 2012 | By Roche
First medicine approved to treat influenza in infants two weeks of age and older...
18 December 2012 | By Roche
Roche announced the global launch (excluding US) of cobas b 101...
14 December 2012 | By Roche
Positive opinion for the use of Perjeta (pertuzumab)...